Cervical cancer screening among HIV-infected women: An economic evaluation in a middle-income country

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages

  Vanni, Tazio ^a   Luz, Paula Mendes ^b   Grinsztejn, Beatriz ^b   Veloso, Valdilea G ^b   Foss, Anna ^a   Mesa Frias, Marco ^a   Legood, Rosa ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Funda??o Oswaldo Cruz   (Brazil)

Author keywords

cervical cancer; cost effectiveness; economic evaluation; human papillomavirus; screening

Indexed keywords

ADULT; AGED; ARTICLE; BRAZIL; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEALTH CARE COST; HPV DNA TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIFE EXPECTANCY; MATHEMATICAL MODEL; PAPANICOLAOU TEST; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; YEAR OF LIFE SAVED;

EID: 84861598278     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26472     Document Type: Article

References (50)

1. UNAIDS. AIDS epidemic update 2009. Joint United Nations Programme on HIV/AIDS. Accessed on November 6, 2010.
2. Palefsky JM,. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol. 2003; 15: 382-8.
3. Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, Hall C, Bacon M, Levine AM, Watts DH, Silverberg MJ, Xue X, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005; 97: 577-86.
4. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S,. Human papillomavirus and cervical cancer. Lancet. 2007; 370: 890-907.
5. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005; 97: 425-32.
6. Franceschi S, Jaffe H,. Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy. Clin Infect Dis. 2007; 45: 510-3.
7. Campos DP, Ribeiro SR, Grinsztejn B, Veloso VG, Valente JG, Bastos FI, Morgado MG, Gadelha AJ,. Survival of AIDS patients using two case definitions, Rio de Janeiro, Brazil, 1986-2003. Aids 2005; 19 Suppl 4: S22-6.
8. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ,. Trends in cancer risk among people with AIDS in the United States 1980-2002. Aids. 2006; 20: 1645-54.
9. Franceschi S, Dal Maso L, Pezzotti P, Polesel J, Braga C, Piselli P, Serraino D, Tagliabue G, Federico M, Ferretti S, De Lisi V, La Rosa F, et al. Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998. J Acquir Immune Defic Syndr. 2003; 34: 84-90.
10. Orem J, Otieno MW, Remick SC,. AIDS-associated cancer in developing nations. Curr Opin Oncol. 2004; 16: 468-76.
11. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF,. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer. 2004; 109: 418-24.
12. INCA. Estimativa 2010: Incidência do câncer no Brasil. Instituto Nacional do Câncer. Ministério da Sáude. Rio de Janeiro. Brasil 2009: 94. Available at: http://www.inca.gov.br/estimativa/ 2010/.
13. Arbyn M, Buntinx F, Ranst MV, Paraskevaidis E, Martin-Hirsch P, Dillner J,. Virologic versus cytologic triage of women with equivocal pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004; 96: 280-93.
14. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand M-H, Dillner J, Meijer CJLM,. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26: K29-K41.
15. Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards-Kortum R,. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998; 91: 626-31.
16. Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA,. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in hiv-infected women. Ann Intern Med. 1999; 130: 97-107.
17. Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM,. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med. 2001; 111: 140-49.
18. Grinsztejn B, Veloso VG, Levi JE, Velasque L, Luz PM, Friedman RK, Andrade AC, Moreira RI, Russomano F, Pilotto JH, Bastos FI, Palefsky J,. Factors associated with increased prevalence of human papillomavirus infection in a cohort of HIV-infected Brazilian women. Int J Infect Dis. 2009; 13: 72-80.
19. Grinsztejn B, Bastos FI, Veloso VG, Friedman RK, Pilotto JH, Schechter M, Derrico M, Andrade A, Lourenco MC, Moreira RI, Russomano F, Morgado M, et al. Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil. Int J STD AIDS. 2006; 17: 473-8.
20. Vanni T, Legood R, Franco EL, Villa LL, Luz PM, Schwartsmann G,. Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. Int J Cancer 2011; 129: 671-9.
21. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJF, Meijer CJLM, the International Agency for Research on Cancer Multicenter Cervical Cancer Study G,. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med. 2003; 348: 518-27.
22. Pecorelli S NH, Hacker NF,. Staging classification and clinical practice guidelines for gynaecological cancers.
23. Miners A, Sabin C, Trueman P, Youle M, Mocroft A, Johnson M, Beck E,. Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med. 2001; 2: 52-58.
24. Berkhof J, Coupé VM, Bogaards JA, Kemenade FJv, Helmerhorst TJ, Snijders PJ, Meijer CJ,. The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer. 2010; 127: 2147-58.
25. Legood R, Gray A, Wolstenholme J, Moss S,. Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: Modelling study. Br Med J. 2006; 332: 79-83.
26. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ,. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol. 2007; 166: 137-50.
27. Jit M, Gay N, Soldan K, Choi YH, Edmunds WJ,. Estimating progression rates for human papillomavirus infection from epidemiological data. Med Decis Making. 2009; 30: 84-98.
28. Diaz M, de Sanjose S, Ortendahl J, O'Shea M, Goldie SJ, Bosch FX, Kim JJ,. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer. 2010; 46: 2973-85.
29. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ,. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst. 2008; 100: 308-20.
30. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB,. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000; 132: 810-19.
31. Goldhaber-Fiebert J, Stout N, Ortendahl J, Kuntz K, Goldie S, Salomon J,. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metrics 2007; 5: 11.
32. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB,. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000; 151: 1158-71.
33. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, Rohan TE,. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999; 180: 1415-23.
34. Molano M, van den Brule AJC, Posso H, Weiderpass E, Ronderos M, Franceschi S, Meijer CJLM, Arslan A, Munoz N,. Low grade squamous intra-epithelial lesions and human papillomavirus infection in Colombian women. Br J Cancer. 2002; 87: 1417-21.
35. Molano M, Posso H, Weiderpass E, van den Brule AJC, Ronderos M, Franceschi S, Meijer CJLM, Arslan A, Munoz N,. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer. 2002; 87: 324-33.
36. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, Ferenczy A, Rohan TE, Villa LL, Franco EL,. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst. 2003; 95: 1336-43.
37. Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'Shea MKH, Xavier Bosch F, de Sanjosé S, Franco EL,. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine. 2007; 25: 6257-70.
38. Vanni T, Karnon J, Madan J, White RG, Edmunds WJ, Foss AM, Legood R,. Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics 2011; 29: 35-49 10.2165/11584600-000000000-00000.
39. INCA. Nomenclatura brasileira para laudos cervicais e condutas preconizadas: recomendações para profissionais de saúde. Instituto Nacional do Cancer. Ministério da Saude. Rio de Janeiro, Brasil, 2006.
40. Nomenclatura Brasileira para laudos cervicais e condutas preconizadas. Instituto Nacional do Cancer (INCA), 2006, edn. Second Rio de Janeiro, Brazil. Available at: http://portalsbc.com.br/nomeclaturas.pdf.
41. The World Factbook. Central Intelligence Agency. 2009.
42. Methodological guidelines for appraisals on health technology assessment for the Ministry of Health of Brazil., vol. Brasilia, 2008.
43. Briggs A, Claxton K, Sculpher M,. Decision Modelling for Health Economic Evaluation, 1st edn. Oxford: Oxford University Press, 2006.
44. WHO. Macroeconomics and health: investing in health for economic development: report of the commission on macroeconomics and health. Geneva: World Health Organization, 2001.
45. Goldie SJ, Diaz M, Kim S-Y, Levin CE, Van Minh H, Kim JJ,. Mathematical Models of Cervical Cancer Prevention in the Asia Pacific Region. Vaccine 2008; 26: M17-M29.
46. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, Wright TC,. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005; 353: 2158-68.
47. The World Economic Outlook Database. International Monetary Fund. 2010.
48. Pretorius RG, Zhang W-H, Belinson JL, Huang M-N, Wu L-Y, Zhang X, Qiao Y-L,. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol. 2004; 191: 430-4.
49. Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, Mantovani L, Capri S, Chou C-Y, Standaert B, Annemans L,. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 2008; 26: F16-F28.
50. Classificacao Brasileira Hierarquizada de Procedimentos Medicos, 5th edn. 2008.